These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35472699)

  • 1. Use of immunotherapy in clinical management of genitourinary cancers - a review.
    Mar N; Uchio E; Kalebasty AR
    Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape of Immunotherapy in Genitourinary Malignancies.
    Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
    Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
    Lu K; Chiu KY; Cheng CL
    Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma.
    Zeuschner P; Junker K
    Eur Urol Focus; 2022 Jul; 8(4):907-909. PubMed ID: 35918269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Kato M; Uchida J
    Int J Urol; 2023 Dec; 30(12):1068-1077. PubMed ID: 37602512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-Oncology Advances in Genitourinary Cancers.
    Zang PD; Angeles A; Dorff TB; Pal SK; Gupta S
    Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430428. PubMed ID: 38206274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors.
    Bahlinger V; Hartmann A; Eckstein M
    Adv Anat Pathol; 2023 May; 30(3):203-210. PubMed ID: 36730368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis.
    Maisch P; Koll F; Bolenz C; Chun FK; Gschwend JE; Schmid SC
    Urol Oncol; 2023 May; 41(5):219-232. PubMed ID: 36372634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
    Surolia I; Gulley J; Madan RA
    Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibition in upper tract urothelial carcinoma.
    Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
    World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current State of Cell Therapies for Genitourinary Malignancies.
    Alkhouli MA; Bazargan S; Pilon-Thomas S; Poch M; Chahoud J
    Cancer J; 2022 Jul-Aug 01; 28(4):294-300. PubMed ID: 35880939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.
    Labadie BW; Balar AV; Luke JJ
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on immunotherapy for renal cancer.
    Canales Rojas R
    Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.